Profile data is unavailable for this security.
About the company
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
- Revenue in USD (TTM)520.00k
- Net income in USD-201.40m
- Incorporated1990
- Employees141.00
- LocationGeron Corp919 East Hillsdale Boulevard, Suite 250FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 473-7700
- Fax+1 (302) 655-5049
- Websitehttps://www.geron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.19bn | 570.00 | -- | 5.33 | -- | 8.00 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.65 | -- | 12.64 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Fortrea Holdings Inc | 3.01bn | -100.60m | 2.22bn | 16.00k | -- | 1.40 | -- | 0.7397 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Vericel Corp | 207.78m | 451.00k | 2.23bn | 314.00 | 4,808.58 | 9.53 | 413.74 | 10.75 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.24bn | 526.00 | -- | 2.16 | -- | 42.64 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.27bn | 557.00 | -- | 3.33 | -- | 1,190.47 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.34bn | 624.00 | -- | 15.21 | 490.46 | 8.26 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| CG Oncology Inc | 539.00k | -72.33m | 2.35bn | 61.00 | -- | 4.13 | -- | 4,359.43 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.35bn | 226.00 | -- | 38.19 | -- | 25.59 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Geron Corp | 520.00k | -201.40m | 2.37bn | 141.00 | -- | 6.79 | -- | 4,551.15 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.46bn | 1.45k | -- | 6.83 | -- | 4.67 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.49bn | 1.54k | -- | -- | -- | 2.50 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 2.51bn | 284.00 | 73.52 | 15.65 | 60.56 | 8.66 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.52bn | 64.00 | -- | 3.84 | -- | 345.24 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 2.53bn | 111.00 | -- | 5.89 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Geron Corp's reporting currency: US Dollar USD
38.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 46.20m | 7.86% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 37.12m | 6.31% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 31.60m | 5.37% |
| Deep Track Capital LPas of 31 Mar 2024 | 30.51m | 5.19% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 28.72m | 4.89% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 12.76m | 2.17% |
| Geode Capital Management LLCas of 31 Mar 2024 | 11.43m | 1.94% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 10.94m | 1.86% |
| Logos Global Management LPas of 31 Mar 2024 | 9.00m | 1.53% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 7.50m | 1.28% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
